Evaluation of the use of Favipiravir on the Hematology value of COVID-19 patients at Anna Bekasi Hospital in 2021

Feri Setiadi; Ardy Tanfil T; Widyastuti Widyastuti

doi:10.30595/pharmacy.v0i0.15776

Evaluation of the use of Favipiravir on the Hematology value of COVID-19 patients at Anna Bekasi Hospital in 2021

Feri Setiadi, Ardy Tanfil T, Widyastuti Widyastuti

Abstract

The COVID-19 pandemic caused by the SARS-CoV-2 virus occurred in Indonesia in early 2020. Favipiravir was used as an antiviral for the disease due to an emergency. The results of routine hematological examinations of inpatients can be used as a parameter to predict the patient's risk of severity and the effect of using favipiravir antiviral. This study aimed to determine the effect of using favipiravir on hematological values in COVID-19 patients. The method used in this research is cross-sectional. The data collection method was carried out retrospectively with the data source in the form of medical records at Anna Bekasi Selatan Hospital in 2021. The total sample that included the inclusion criteria in this study was 83 patients. The results of the study between before and after the use of favipiravir in patients without comorbidities were significant differences in the values of the Neutrophil Lymphocyte Ratio (p: 0.003), Lymphocytes (p: 0.000), Platelets (p: 0.009) while in the value of hematocrit (p: 0.185) ) and hemoglobin (p:0.069) did not experience a significant difference. Patients with comorbid comorbidities using favipiravir had significant differences in hematological values, namely hemoglobin (p: 0.007), hematocrit (p: 0.004), platelets (p: 0.000) while the value of the Neutrophil Lymphocyte Ratio (p: 0.260) and lymphocytes (p: 0.234) did not experience a significant difference. Favipiravir is known to have a positive correlation with hematological values, in patients with COVID-19 infection without comorbidities using favipiravir it is known that the Neutrophil Lymphocyte Ratio value has decreased while the Lymphocyte and Platelet values have increased. However, it is known that the hemoglobin and hematocrit values did not experience a significant difference before consuming favipiravir and after consuming favipiravir.

Keywords

COVID-19; Favipiravir; Hematological Valu

References

Anai, M., Akaike, K., Iwagoe, H., Akasaka, T., Higuchi, T., Miyazaki, A., Naito, D., Tajima, Y., Takahashi, H., Komatsu, T., Masunaga, A., Kishi, H., Fujii, K., Fukuda, K., Tomita, Y., Saeki, S., Ichiyasu, H., Sakagami, T., 2021. Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-199 patients with pneumonia. Respiratory Investigation, 59, 187–193.

Atcali, T., Yakut, S., Çaǧlayan, C., Ulucan, A., Kara, A., 2022. Effects of favipiravir on hematologic parameters and bone marrow in the rats. Journal of Experimental and Clinical Medicine (Turkey), 39, 156–159.

Fard, M.B., Fard, S.B., Ramazi, S., Atashi, A., Eslamifar, Z., 2021. Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity. Thrombosis Journal, 19, 59.

Halil, F., Anwar, M.W., Sundari, S., 2022. Netrophil-lymphocyte ratio (NLR) as a predictor of severity in Covid-19 patients. Jurnal Biologi Tropis, 22, 455–460.

Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., Barkate, H., 2021. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases, 102:501-508, doi: 10.1016/j.ijid.2020.10.069.

Kong, M., Zhang, H., Cao, X., Mao, X., Lu, Z., 2020. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiology Infection, 148, e139.

Łagocka, R., Dziedziejko, V., Kłos, P., Pawlik, A., 2021. Favipiravir in therapy of viral infections. Journal of Clinical Medicine. 10(2), 273. doi: 10.3390/jcm10020273.

McHutchison, J.G., Manns, M.P., Brown, R.S., Reddy, K.R., Shiffman, M.L., Wong, J.B., 2007. Strategies for managing anemia in hepatitis c patients undergoing antiviral therapy. Journal of the American College of Gastroenterology, 102(4), 880-9. doi: 10.1111/j.1572-0241.2007.01139.x.

Mintzer, D.M., Billet, S.N., Chmielewski, L., 2009. Drug-induced hematologic syndromes. Advanced Hematology.

Mus, R., Thaslifa, T., Abbas, M., Sunaidi, Y., 2021. Studi literatur: Tinjauan pemeriksaan laboratorium pada pasien COVID-19. Jurnal Kesehatan Vokasional 5, 242.

Ozbas, H.M., Kayan, T., Yakarisik, M., Dulger, A.C., Ayvaz, M.A., Aydin, M., 2021. Role of favipiravir on the hematologic parameters in patients with COVID-19 infection. Medical Science and Discovery, 8, 577–580.

Özlüşen, B., Kozan, Ş., Akcan, R.E., Kalender, M., Yaprak, D., Peltek, İ.B., Keske, Ş., Gönen, M., Ergönül, Ö., 2021. Effectiveness of favipiravir in COVID-19: A live systematic review. European Journal of Clinical Microbiology and Infectious Diseases, 40, 2575–2583.

Shereen, M.A., Khan, S., Kazmi, A., Bashir, N., Siddique, R., 2020. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91–98.

Shinkai, M., Tsushima, K., Tanaka, S., Hagiwara, E., Tarumoto, N., Kawada, I., Hirai, Y., Fujiwara, S., Komase, Y., Saraya, T., Koh, H., Kagiyama, N., Shimada, M., Kanou, D., Antoku, S., Uchida, Y., Tokue, Y., Takamori, M., Gon, Y., Ie, K., Yamazaki, Y., Harada, K., Miyao, N., Naka, T., Iwata, M., Nakagawa, A., Hiyama, K., Ogawa, Y., Shinoda, M., Ota, S., Hirouchi, T., Terada, J., Kawano, S., Ogura, T., Sakurai, T., Matsumoto, Y., Kunishima, H., Kobayashi, O., Iwata, S., 2021. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: A randomized, phase III clinical trial. Infectious Diseases and Therapy, 10, 2489–2509.

Singhal, T., 2020. A review of coronavirus disease-2019 (COVID-19). Indian Journal of Pediatrics, 87(4), 281-286. doi: 10.1007/s12098-020-03263-6

Tawfik, A., Alzahrani, Abdulrahman, Alharbi, S., Almitairi, J., Alzahrani, Arwa, Alshehri, M.A., Aldughaim, M.S., Alothaid, H., 2022. Effectiveness of early favipiravir therapy in hospitalised COVID-19 patients. Advances in Virology, 9240941, doi: 10.1155/2022/9240941.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA, 323(11), 1061-1069. doi: 10.1001/jama.2020.1585.

Yaylaci, S., Dheir, H., Şenocak, D., Genc, A.B., Kocayigit, H., Çekiç, D., Varım, C., Aydın, A., Koroglu, M., Karabay, O., 2020. The effects of favipiravir on hematological parameters of covıd-19 patients. Revista da Associação Médica Brasileira, 66, 65–70

Full Text: PDF

DOI: 10.30595/pharmacy.v0i0.15776

Copyright (c) 2023 PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia)

This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN: 2579-910X